Physician profile
Nikhil Dhingra
NPI 1881012763
$4,457.21
in general payments reported to CMS, 2019-2025
24 companies · $554 in 2025
The $554 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $634 · 2021: $1,060 · 2022: $497 · 2023: $565 · 2024: $510 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.78 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $650.00 | 2019-2025 | |
| Janssen Biotech, INC. | $436.09 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $288.33 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $272.80 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $226.71 | 2019-2022 | |
| Allergan, INC. | $218.14 | 2020-2022 | |
| Leo Pharma INC. | $191.61 | 2020-2023 | Adbry |
| Mayne Pharma Commercial LLC | $187.99 | 2019-2023 | |
| Lilly USA, LLC | $187.47 | 2019-2024 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $165.38 | 2020-2024 | Absorica Ld, Winlevi |
| Genzyme Corporation | $157.53 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $119.74 | 2019 | |
| Vyne Pharmaceuticals INC. | $93.24 | 2020-2021 | |
| Dermavant Sciences, INC. | $91.09 | 2023-2024 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $86.22 | 2019-2023 | |
| Dermira, INC. | $78.27 | 2019-2020 | |
| Amgen INC. | $66.45 | 2020-2021 | |
| Almirall LLC | $41.11 | 2022-2023 | Seysara |
| Celgene Corporation | $23.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.51 | 2024 | Sotyktu |
| Acelrx Pharmaceuticals, INC. | $18.11 | 2021 | |
| Aclaris Therapeutics, INC. | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Dhingra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.